CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
ACC 2019Cardiovascular ImagingCoronary Artery DiseaseMicrovascular dysfunctionVasospastic angina

Enhanced Vasospasm And Reduced Vasodilator Function Linked To Worse Outcomes In Patients With Non-Obstructive Coronary Arteries

Syed Hassan Kazmi M.D.
Share
4 Min Read

A single center study that included 187 patients who presented with angina-like chest pain and nonobstructive coronary arteries on diagnostic angiography, has shown that co-existence of high microvascular resistance index (IMR) and vasospasm is associated with an increased incidence of major adverse cardiovascular events (MACE – defined as cardiac death, nonfatal myocardial infarction, and hospitalizations). Rho-kinase activation thought to underlie mechanisms leading to high IMR in this patient population.
The 187 patients included in the study had a median follow-up of 893 days.

The results of the study were published this month in Journal of American College of Cardiology (JACC). The authors found that IMR correlated with the incidence of cardiac events (hazard ratio: 1.05; 95% confidence interval: 1.02 to 1.09; p = 0.002) and receiver-operating characteristics (ROC) curve analysis revealed IMR of 18.0 as the best cut-off (sensitivity 90%, specificity 63.4%, negative predictive value 99.1%). Patients were divided into 4 groups based on presence or absence of vasospastic angina (VSA) and IMR < 18 or > 18. It was found that out these 4 groups, the group with vasospastic angina (VSA) and IMR greater than equal to 18 had the highest incidence of MACE (HR: 6.23, 95% CI : 1.21-118.48, p = 0.03). According to the authors, this highlights that patients with both enhanced coronary vasoconstrictive reactivity and reduced vasodilator function are at high risk for future MACE.

Subjects were selected based on the presence of main vessel luminal narrowing<70% and/or fractional flow reserve [FFR] >0.8 with further exclusion of patients who had cardiomyopathy, significant valvular diseases (e.g., aortic stenosis), previous coronary stent implantation, relative contraindication for provocation test (e.g., bronchial asthma), renal failure, poor general condition, and those who had unsuccessful procedures during physiological measurement and/or acetylcholine (Ach) provocation test. Ach provocation test was done to identify subjects suffering from vasospastic angina (VSA). Coronary flow was determined using variables such as coronary flow reserve (CFR), FFR and IMR measured subsequent to administration vasodilatory intracoronary isosorbide dintrate. The authors also assessed the role of rho-kinase activation on reduced cardiac vasodilation by administering fasudil, a rho-kinase inhibitor and then calculating the percent change in IMR from pre-fasudil exposed coronary arteries.
In patients with VSA, CFR was negatively correlated with IMR. Further, this negative correlation was also observed between CFR and percent change in IMR after intracoronary fasudil, thereby implicating a role of rho-kinase activation in increased microvascular resistance. This patient population remains at a higher risk for MACE despite receiving treatment with calcium channel blockers, nitrate and nicorandil. Since the coronary vessels in VSA have non-obstructive stenosis, microvascular dysfuntion underlies the bad prognosis seen in these patients.

The study has some limitations, the first being that the study was single-center which necessitates further multi-center studies in order to consolidate the findings. Secondly, there were only 10 MACE events in the cohort, which may have led to a reduction in the statistical power of the results. Third, only left anterior descending (LAD) was evaluated for physiological measurements of coronary blood flow and circumflex arteries were not used for this purpose. Fourth, 14% of patients with microvascular spasm were inaccurately classified into non-VSA group and did not have their hemodynamic profiling performed. Fifth, VSA is known to more commonly affect females and the present study included 60% men which may have produced discrepancies in findings. Lastly, information regarding the changes in medical therapy, adherence to the therapy, and symptom and/or quality of life (e.g., Seattle Angina Questionnaire) during the follow-up was not available to the investigators.

TAGGED:FeaturedNews
Share This Article
Copy Link Print
Leave a Comment

Leave a Reply Cancel reply

You must be logged in to post a comment.

CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?